Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 41

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
The following table summarizes our total revenue (in thousands):

Six Months Ended June 30,20252024Increase / (decrease)% Increase / (decrease)Revenue from sale of therapies, net$191,845 $145,689 $46,156 31.7 %Collaboration revenue— 213 (213)(100.0)%Total revenue$191,845 $145,902 $45,943 31.5 %

21

Table of Contents

Revenue from sale of therapies, net

Revenue from sale of therapies, net is presented by country / region based on location of the end customer below (in thousands).Six Months Ended June 30,20252024Increase / (decrease)% Increase / (decrease)United States$120,694 $105,632 $15,062 14.3 %Europe65,846 34,356 31,490 91.7 %International5,305 5,701 (396)(6.9)%Revenue from sale of therapies, net$191,845 $145,689 $46,156 31.7 %

For the six months ended June 30, 2025, we generated revenue from sale of therapies, net of $191.8 million, due to the sale of KIMMTRAK, of which $120.7 million was in the United States, $65.8 million in Europe (including the impact of a net decrease in estimated reserves related to prior periods of $6.0 million) and $5.3 million in International. Revenue from sale of therapies, net increased in the six months ended June 30, 2025 compared to the six months ended June 30, 2024, due primarily to increased volume in the United States and Europe as well as global country expansion. This was partially offset by fewer shipments in international regions, primarily due to timing of orders.

R&D Expenses

The following table summarizes our R&D expenses (in thousands):

Six Months Ended June 30,20252024Increase / (decrease)% Increase / (decrease)External R&D expenses:PRAME programs$37,983 $48,632 $(10,649)(21.9)%Tebentafusp programs18,407 10,451 7,956 76.1 %Infectious disease programs2,730 3,685 (955)(25.9)%All other